Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2013-02-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-12-1020PMID 23443802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Metabolic Syndrome and Cancer

  2013cited by this paper
• Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma.

  2012cited by this paper
• Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.

  2012cited by this paper
• Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

  2012cited by this paper
• Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

  2012cited by this paper
• Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner

  2012cited by this paper
• AACR Cancer Progress Report 2012

  2012cited by this paper
• A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

  2011cited by this paper
• Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.

  2011influential reference
• The AMPK signalling pathway coordinates cell growth, autophagy and metabolism

  2011cited by this paper
• Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow?

  2011cited by this paper
• Harnessing the cell death pathway for targeted cancer treatment.

  2011cited by this paper
• The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

  2010cited by this paper
• Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

  2010cited by this paper
• Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

  2010cited by this paper
• Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Mutations in GNA11 in uveal melanoma.

  2010cited by this paper
• Life and death partners: apoptosis, autophagy and the cross-talk between them

  2009cited by this paper
• High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

  2009cited by this paper
• Safingol (l-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway

  2009cited by this paper
• The LKB1–AMPK pathway: metabolism and growth control in tumour suppression

  2009cited by this paper
• Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.

  2008influential reference
• Oncogenic mutations in GNAQ occur early in uveal melanoma.

  2008cited by this paper
• Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

  2008cited by this paper
• Galphaq binds two effectors separately in cells: evidence for predetermined signaling pathways.

  2008cited by this paper
• AMPK phosphorylation of raptor mediates a metabolic checkpoint.

  2008cited by this paper
• Mitogenic signaling pathways induced by G protein‐coupled receptors

  2007cited by this paper
• AMP-Activated Protein Kinase: A Universal Regulator of Autophagy?

  2007cited by this paper
• Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins.

  2006cited by this paper
• Gαq binds to p110α/p85α phosphoinositide 3-kinase and displaces Ras

  2006cited by this paper
• Cell signalling diversity of the Gqα family of heterotrimeric G proteins

  2006cited by this paper
• Autophagic programmed cell death by selective catalase degradation.

  2006cited by this paper
• Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras.

  2006cited by this paper
• AMP-activated Protein Kinase and the Regulation of Autophagic Proteolysis*

  2006cited by this paper
• Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS

  2005cited by this paper
• AMPK, the metabolic syndrome and cancer.

  2005cited by this paper
• The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

  2005cited by this paper
• Regulation of an ATG7-beclin 1 Program of Autophagic Cell Death by Caspase-8

  2004cited by this paper
• Autophagy: a regulated bulk degradation process inside cells.

  2004cited by this paper
• Survival rates with uveal melanoma in the United States: 1973-1997.

  2003cited by this paper
• Very long-term prognosis of patients with malignant uveal melanoma.

  2003cited by this paper
• Dual Regulation of Akt/Protein Kinase B by Heterotrimeric G Protein Subunits*

  2000cited by this paper
• Autophagy as a regulated pathway of cellular degradation.

  2000cited by this paper
• Induction of autophagy and inhibition of tumorigenesis by beclin 1

  1999cited by this paper
• Activation of Akt/Protein Kinase B by G Protein-coupled Receptors

  1998cited by this paper
• Establishment and characterization of primary and metastatic uveal melanoma cell lines

  1996influential reference
• Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors

  1996cited by this paper

• Management of liver metastases from uveal melanoma

  2025cites this paper
• Allele-specific depletion of GNAQQ209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in GNAQQ209L uveal melanoma cells

  2025cites this paper
• The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms

  2024cites this paper
• Biological characteristics and clinical management of uveal and conjunctival melanoma

  2024cites this paper
• Heterogeneity and molecular landscape of melanoma: implications for targeted therapy

  2024cites this paper
• The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma.

  2024cites this paper
• The multiple roles of autophagy in uveal melanoma and the microenvironment

  2024cites this paper
• Modulation of AMPK Significantly Alters Uveal Melanoma Tumor Cell Viability

  2023cites this paper
• PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation

  2023cites this paper
• LINC01278 Induces Autophagy to Inhibit Tumour Progression by Suppressing the mTOR Signalling Pathway

  2023cites this paper
• Advances in the clinical management of uveal melanoma

  2023cites this paper
• Uveal melanoma modeling in mice and zebrafish.

  2023cites this paper
• Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma

  2023cites this paper
• The "Self-eating" of cancer-associated fibroblast: A potential target for cancer.

  2023cites this paper
• Targeted Therapy for Melanomas Without BRAF V600 Mutation

  2022cites this paper
• Role of the AMPK signalling pathway in the aetiopathogenesis of ocular diseases

  2022cites this paper
• Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling

  2022cites this paper
• Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma

  2022cites this paper
• Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen

  2022cites this paper
• Targeting Oncogenic Gαq/11 in Uveal Melanoma

  2021cites this paper
• Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma

  2021influential citation
• Immune implication of an autophagy-related prognostic signature in uveal melanoma

  2021cites this paper
• Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy

  2021cites this paper
• Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma

  2021cites this paper
• Prognostic Value of Autophagy-related Genes Correlated With Metastasis in Uveal Melanoma Patients

  2021cites this paper
• Development of new therapeutic options for the treatment of uveal melanoma

  2021cites this paper
• Autophagy-Related Long Non-coding RNA Signature as Indicators for the Prognosis of Uveal Melanoma

  2021cites this paper
• Somatic GNAQ R183Q mutation is located within the sclera and episclera in patients with Sturge-Weber syndrome

  2021cites this paper
• ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression

  2020cites this paper
• Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition

  2020cites this paper
• Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma

  2020cites this paper
• Uveal melanoma: progress in molecular biology and therapeutics

  2020cites this paper
• A review of prognostic biomarkers in uveal melanomas

  2020cites this paper
• Novel Approaches to the Systemic Management of Uveal Melanoma

  2020cites this paper
• Sirolimus as a Potential Treatment for Sturge-Weber Syndrome

  2020cites this paper
• Systemic Therapy for Mucosal, Acral, and Uveal Melanoma

  2020cites this paper
• Recent insights into apoptosis and toxic autophagy: the roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.

  2020cites this paper
• Lower Levels of Adiponectin and Its Receptor Adipor1 in the Uveal Melanomas With Monosomy-3

  2020cites this paper
• Direct targeting of Gαq and Gα11 oncoproteins in cancer cells

  2019cites this paper
• Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives

  2019cites this paper
• Mouse models of uveal melanoma: Strengths, weaknesses, and future directions

  2019cites this paper
• Preventive treatment with oral sirolimus and aspirin in a newborn with severe Sturge‐Weber syndrome

  2019cites this paper
• Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma

  2019cites this paper
• Systemic Therapy for Mucosal, Acral and Uveal Melanoma

  2019cites this paper
• Mutation spectrum in GNAQ and GNA11 in Chinese uveal melanoma

  2019cites this paper
• Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

  2018cites this paper
• How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.

  2018cites this paper
• Rôle de la phosphatase PRL-3 et de CRMP2 dans la migration et l'invasion du mélanome uvéal

  2018cites this paper
• Oncogenic signaling in uveal melanoma

  2018cites this paper
• Selumetinib-based therapy in uveal melanoma patient-derived xenografts

  2018cites this paper
• Genetic prognostication in uveal melanoma

  2018cites this paper
• R

  2018cites this paper
• Treatment of uveal melanoma: where are we now?

  2018cites this paper
• Potential biological targets for bioassay development in drug discovery of Sturge–Weber syndrome

  2017cites this paper
• Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma

  2017cites this paper
• The role of sodium hydrosulfide in attenuating the aging process via PI3K/AKT and CaMKKβ/AMPK pathways

  2017cites this paper
• Revealing differential modules in uveal melanoma by analyzing differential networks.

  2017cites this paper
• BRAF V600E-dependent role of autophagy in uveal melanoma

  2017cites this paper
• AMPK: Therapeutic Target for Diabetes and Cancer Prevention.

  2017cites this paper
• Metastatic Uveal Melanoma—A Review of Current Therapies and Future Directions

  2017cites this paper
• Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.

  2017cites this paper
• Recent advances in uveal melanoma treatment

  2017cites this paper
• Novel therapeutic strategies and targets in advanced uveal melanoma

  2017cites this paper
• Gr upSM Signaling Pathways and Potential Molecular Targets in Uveal Melanoma

  2017cites this paper
• Implications of MEK and VEGFR2 inhibition on melanoma CXCR4-CXCL12 chemotaxis, survival and tumour progression

  2017influential citation
• Uveal Melanoma: Current Trends in Diagnosis and Management

  2016cites this paper
• Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.

  2016cites this paper
• The role of mitogen-activated protein targeting in melanoma beyond BRAFV600

  2016cites this paper
• A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature

  2016cites this paper
• Selumetinib for the treatment of melanoma

  2016cites this paper
• Autophagy in Ocular Pathophysiology

  2016cites this paper
• Clinical Management of Uveal and Conjunctival Melanoma.

  2016cites this paper
• Clinical presentation and management of uveal melanoma.

  2016cites this paper
• Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells

  2016cites this paper
• The Evolving Functions of Autophagy in Ocular Health: A Double-edged Sword

  2016cites this paper
• Metastatic disease from uveal melanoma: treatment options and future prospects

  2016cites this paper
• Treatment of Uveal Melanoma.

  2016cites this paper
• P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma

  2016cites this paper
• Genomic and Functional Studies of Uveal Melanoma

  2015influential citation
• Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

  2015cites this paper
• BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells

  2015cites this paper
• Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects

  2015cites this paper
• Achievements and challenges of molecular targeted therapy in melanoma.

  2015cites this paper
• Targeting AMPK for cancer prevention and treatment

  2015cites this paper
• Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

  2015cites this paper
• Selumetinib for the treatment of cancer

  2015cites this paper
• Recent developments in prognostic and predictive testing in uveal melanoma

  2014cites this paper
• Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.

  2014cites this paper
• Identification of novel therapeutic strtegies for Uveal Melanoma

  2014cites this paper
• Cancer Biology and Signal Transduction Overexpression of DDX 43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

  2014cites this paper
• Small Molecule Therapeutics The Phosphoinositide 3-Kinase a Selective Inhibitor BYL 719 Enhances the Effect of the Protein Kinase C Inhibitor AEB 071 in GNAQ / GNA 11-Mutant Uveal Melanoma Cells

  2014cites this paper
• Melanoma: clinical features and genomic insights.

  2014cites this paper
• Biology of advanced uveal melanoma and next steps for clinical therapeutics

  2014influential citation
• Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma

  2014influential citation
• Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

  2014cites this paper
• MEK inhibitor effective against proliferation in breast cancer cell

  2014cites this paper
• Inhibition of autophagy promotes caspase-mediated apoptosis by tunicamycin in HepG2 cells

  2014cites this paper
• Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas

  2014cites this paper
• Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

  2014influential citation
• Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

  2014cites this paper